Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rxo (RXO) EBITDA (2021 - 2025)

Historic EBITDA for Rxo (RXO) over the last 5 years, with Q4 2025 value amounting to -$42.0 million.

  • Rxo's EBITDA fell 7500.0% to -$42.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$79.0 million, marking a year-over-year decrease of 4107.14%. This contributed to the annual value of -$79.0 million for FY2025, which is 4107.14% down from last year.
  • Rxo's EBITDA amounted to -$42.0 million in Q4 2025, which was down 7500.0% from -$7.0 million recorded in Q3 2025.
  • Rxo's EBITDA's 5-year high stood at $58.0 million during Q2 2022, with a 5-year trough of -$42.0 million in Q4 2025.
  • For the 5-year period, Rxo's EBITDA averaged around $7.5 million, with its median value being $5.5 million (2023).
  • Its EBITDA has fluctuated over the past 5 years, first soared by 150000.0% in 2023, then crashed by 43333.33% in 2024.
  • Over the past 5 years, Rxo's EBITDA (Quarter) stood at $55.0 million in 2021, then plummeted by 101.82% to -$1.0 million in 2022, then surged by 1500.0% to $14.0 million in 2023, then tumbled by 271.43% to -$24.0 million in 2024, then crashed by 75.0% to -$42.0 million in 2025.
  • Its EBITDA stands at -$42.0 million for Q4 2025, versus -$7.0 million for Q3 2025 and -$30.0 million for Q1 2025.